Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ariel Porcalla"'
Autor:
Andreas Pangerl, Marcello Persico, José A. Carrión, Ariel Porcalla, Michael P. Curry, Francesco Negro, Yao Yu, Juan Turnes, Heiner Wedemeyer, Lois Larsen, Markus Cornberg, Nicole Wick, Ashley Brown, Pietro Lampertico, Eric Crown
Publikováno v:
Journal of Hepatology, Vol. 72, No 6 (2020) pp. 1112-1121
Background & Aims Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1–6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12
Autor:
Margaret Gamalo, Christina Bucci-Rechtweg, Robert M. Nelson, Linh Vanh, Ariel Porcalla, Helen Thackray, Freda Cooner, Lauren Cutler, Danielle Friend, Ron Portman
Publikováno v:
Therapeutic innovationregulatory science. 56(6)
Pediatric drug development lags adult development by about 8 years (Mulugeta et al. in Pediatr Clin 64(6):1185-1196, 2017). In such context, many incentives, regulations, and innovative techniques have been proposed to address the disparity for pedia
Autor:
Ariel Porcalla, Stuart McPherson, Stefan Zeuzem, Ana Gabriela Pires dos Santos, Roger Trinh, Robert J. Fontana, Mark Bondin, Zhenyi Xue, Magdy Elkhashab, Victor Ankoma-Sey, Sabela Lens
Publikováno v:
Advances in Therapy
Introduction The presence or absence of cirrhosis in patients with chronic hepatitis C virus (HCV) infection influences the type and duration of antiviral therapy. Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio in
Autor:
Ariel Porcalla, Cornelia Feiterna-Sperling, Maureen M. Jonas, Robert H. Squires, Antonio Del Valle-Segarra, Chih‐Wei Lin, Kazuhiko Bessho, Teresa I. Ng, Deirdre Kelly, Sandra S. Lovell, Etienne Sokal, Wei Liu, Tatiana Strokova, Yuri Sanchez Gonzalez, Simon C. Ling, Susan M. Rhee, Margaret Burroughs, Loreto Hierro
Publikováno v:
Hepatology (Baltimore, Md.)
The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may incl
Autor:
Federico J. Mensa, Fred Poordad, Tami Pilot-Matias, Magdy Elkhashab, Neddie Zadeikis, Albert Tran, Carolyn M. Setze, Catherine A.M. Stedman, Ariel Porcalla, Marcus A. Wörns, Yao Yu, Stanley Wang, Joaquin Mario Valdes, S. Greenbloom, T. Nguyen, C.-W. Lin, Jean-Pierre Mulkay, Armen Asatryan, Wei Liu, Edward Gane
Publikováno v:
Clinical infectious diseases, 69 (10
Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-f
Autor:
Pietro Lampertico, Robert Flisiak, Nuno Marques, Olivier Clerc, Ioannis Goulis, Mark Bondin, Ariel Porcalla, Zhenzhen Zhang, Yves Horsmans, Harald Hofer, Ella Veitsman, Georges-Philippe Pageaux
Publikováno v:
Journal of Hepatology. 73:S358-S359
Autor:
Philippe J. Zamor, Zhenyi Xue, Annette Bruchfeld, Gretja Schnell, Marwan Kaskas, Eric Lawitz, Meghan E. Sise, Federico J. Mensa, Ariel Porcalla, Andrea Aglitti, Jun Yong Park, Yash J. Jalundhwala, Manal Abunimeh, Marcus-Alexander Wörns, Robert Flisiak, Marcello Persico
Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddccb25ef7198aab76d201a0f28da508
http://hdl.handle.net/11386/4739911
http://hdl.handle.net/11386/4739911
Publikováno v:
Therapeutic innovationregulatory science. 51(6)
Drug-drug interaction (DDIs) are evaluated using pharmacokinetic (PK) simulation models, clinical studies, and scientific publications throughout drug development. DDIs with Norvir (ritonavir) and combination products (eg, Kaletra [lopinavir/ritonavi
Autor:
Ariel Porcalla, Armand Abergel, Neddie Zadeikis, Federico J. Mensa, Edward Gane, Gretja Schnell, Zhenzhen Zhang, Seng Gee Lim, Kinh Nguyen, Joe Sasadeusz, T. Nguyen, Betty B. Yao, Florence Wong, Tarik Asselah, Adam Mahomed, Samuel S. Lee
Publikováno v:
The lancet. Gastroenterologyhepatology. 4(1)
The pangenotypic direct-acting antiviral regimen of glecaprevir coformulated with pibrentasvir is approved to treat chronic hepatitis C virus (HCV) genotype 1-6 infection in adults. In registrational studies, 84 (99%) of 85 patients with HCV genotype
Autor:
Ariel Porcalla, Tram Tran, Armand Abergel, Florence Wong, Katia Alves, Tarik Asselah, Edward Gane, Tuan V. Nguyen, Adam Mahomed, Joe Sasadeusz, Zhenzhen Zhang, Seng Gee Lim, Samuel S. Lee, Preethi Krishnan, Roger Trinh
Publikováno v:
Clinical Hepatology.
Background The pangenotypic direct-acting antivirals (DAAs) glecaprevir (developed by AbbVie and Enanta)/pibrentasvir (G/P) are approved to treat chronic HCV genotype (GT)1–6 infection. In Phase 2 and 3 studies, G/P achieved high SVR12 rates with n